trending Market Intelligence /marketintelligence/en/news-insights/trending/t5GAI8kGGUvaD_MQ1XYwZA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biogen to sell Denmark-based biologics manufacturing site to Fujifilm

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Biogen to sell Denmark-based biologics manufacturing site to Fujifilm

Biogen Inc. agreed to sell its Hillerød, Denmark-based large-scale biologics manufacturing site to Fujifilm Corp. for up to $890 million in cash.

The consideration is subject to minimum purchase commitment guarantees and other contractual terms, Biogen said.

Cambridge, Mass.-based Biogen is selling its subsidiary Biogen (Denmark) Manufacturing ApS, which holds the company's biologics manufacturing operations in the European city.

Following the deal's closing, Tokyo-based Fujifilm will use the Hillerød site to produce third-party products for Biogen, including multiple sclerosis drug Tysabri.

The transaction is subject to closing conditions, including antitrust clearance. The deal is expected to close in the second half of 2019.

Biogen will continue to operate its manufacturing site in Research Triangle Park, N.C. and expects another site, in Solothurn, Switzerland, to be operational by the end of 2020.

As a result of the deal, Biogen expects to see a total after-tax loss of $130 million to $150 million, or 66 cents to 76 cents per diluted share, in the first quarter of 2019.